Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure

Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), for the SURVIVE Investigators, Pentti Põder, Milton Packer(Baylor University Medical Center), Markku S. Nieminen(Cornell University), Robert J. Padley(Abbott (United Kingdom)), Alain Cohen‐Solal(Inserm), Roopal Thakkar(Abbott (United Kingdom)), Stuart Pocock(London School of Hygiene & Tropical Medicine), Franz X. Kleber(Wittenberg University), Matti Kivikko

JAMA

May 1, 2007

10.1001/jama.297.17.1883

Cited by 987

Related Papers

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

|European Heart Journal|2021|13.1k

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|5.4k

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

|New England Journal of Medicine|2021|4.6k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008

|European Journal of Heart Failure|2008|3.5k